Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

Fig. 3

Deterministic sensitivity analysis of resultsa. aAll variables were tested with an upper and lower bound value of + 25 and − 25%, respectively, except for mortality – delayed therapy with + 20 and − 30%, mortality untreated with + 4 and − 30%, and quality of life with + 20 and − 20%, with upper and lower bound values, respectively. IA, invasive aspergillosis; ICER, incremental cost-effectiveness ratio; IV, intravenous; SEK, Swedish krona

Back to article page